Literature DB >> 22320717

Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase.

Kengo Ogawa1, Takeshi Hara, Masahito Shimizu, Soranobu Ninomiya, Junji Nagano, Hiroyasu Sakai, Masato Hoshi, Hiroyasu Ito, Hisashi Tsurumi, Kuniaki Saito, Mitsuru Seishima, Takuji Tanaka, Hisataka Moriwaki.   

Abstract

The escape of preneoplastic cells from the immune system, which is caused by immune tolerance, occurs during the development of several types of tumors. Indoleamine 2,3-dioxygenase (IDO) plays a critical role in the induction of immune tolerance. In the present study we investigated the effects of 1-methyltryptophan (1-MT), an IDO inhibitor, and (-)-epigallocatechin gallate (EGCG), the major catechin in green tea, on the development of azoxymethane (AOM)-induced colonic preneoplastic lesions by focusing on the inhibition of IDO. To induce colonic premalignant lesions, male F344 rats were injected with AOM (20 mg/kg body weight, s.c.) once a week for 2 weeks. They also received 0.2% 1-MT or 0.1% EGCG in their drinking water for 4 weeks, starting 1 week before the first dose of AOM. Both 1-MT and EGCG significantly decreased the total number of aberrant crypt foci and β-catenin-accumulated crypts, which overexpressed IDO protein. Treatment with EGCG decreased IDO mRNA expression in both the colonic epithelium and stroma of rats induced by AOM. The AOM-induced increase in cyclooxygenase-2 mRNA expression in the colonic stroma was significantly decreased by EGCG. Furthermore, AOM-induced increases in IDO activity in the serum and stroma were significantly inhibited by 1-MT and EGCG. Inhibition of IDO activity by 1-MT and EGCG was also observed in cell-free assays. These findings suggest that upregulation of IDO activity is observed in the early stages of colon carcinogenesis and that the use of IDO inhibitors, such as 1-MT and EGCG, which suppress the occurrence of colonic preneoplastic lesions, could be a novel strategy for the chemoprevention of colon cancer.
© 2012 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22320717     DOI: 10.1111/j.1349-7006.2012.02237.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  14 in total

Review 1.  Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.

Authors:  Srikanth Santhanam; David M Alvarado; Matthew A Ciorba
Journal:  Transl Res       Date:  2015-08-03       Impact factor: 7.012

Review 2.  Cancer prevention and therapy through the modulation of the tumor microenvironment.

Authors:  Stephanie C Casey; Amedeo Amedei; Katia Aquilano; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan E Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Sarah Crawford; Hiromasa Fujii; Alexandros G Georgakilas; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Kanya Honoki; W Nicol Keith; Sid P Kerkar; Sulma I Mohammed; Elena Niccolai; Somaira Nowsheen; H P Vasantha Rupasinghe; Abbas Samadi; Neetu Singh; Wamidh H Talib; Vasundara Venkateswaran; Richard L Whelan; Xujuan Yang; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2015-04-10       Impact factor: 15.707

3.  (-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells.

Authors:  Kengo Ogawa; Takeshi Hara; Masahito Shimizu; Junji Nagano; Tomohiko Ohno; Masato Hoshi; Hiroyasu Ito; Hisashi Tsurumi; Kuniaki Saito; Mitsuru Seishima; Hisataka Moriwaki
Journal:  Oncol Lett       Date:  2012-06-15       Impact factor: 2.967

4.  IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice.

Authors:  Ameet I Thaker; M Suprada Rao; Kumar S Bishnupuri; Thomas A Kerr; Lynne Foster; Jeffrey M Marinshaw; Rodney D Newberry; William F Stenson; Matthew A Ciorba
Journal:  Gastroenterology       Date:  2013-05-10       Impact factor: 22.682

5.  Inhibitory effects of a selective prostaglandin E2 receptor antagonist RQ-15986 on inflammation-related colon tumorigenesis in APC-mutant rats.

Authors:  Yohei Shirakami; Takayuki Nakanishi; Noritaka Ozawa; Takayasu Ideta; Takahiro Kochi; Masaya Kubota; Hiroyasu Sakai; Takashi Ibuka; Takuji Tanaka; Masahito Shimizu
Journal:  PLoS One       Date:  2021-05-18       Impact factor: 3.240

6.  Preventive effects of the angiotensin-converting enzyme inhibitor, captopril, on the development of azoxymethane-induced colonic preneoplastic lesions in diabetic and hypertensive rats.

Authors:  Takahiro Kochi; Masahito Shimizu; Tomohiko Ohno; Atsushi Baba; Takafumi Sumi; Masaya Kubota; Yohei Shirakami; Hisashi Tsurumi; Takuji Tanaka; Hisataka Moriwaki
Journal:  Oncol Lett       Date:  2014-05-12       Impact factor: 2.967

7.  The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.

Authors:  Yuhei Shibata; Takeshi Hara; Junji Nagano; Nobuhiko Nakamura; Tomohiko Ohno; Soranobu Ninomiya; Hiroyasu Ito; Takuji Tanaka; Kuniaki Saito; Mitsuru Seishima; Masahito Shimizu; Hisataka Moriwaki; Hisashi Tsurumi
Journal:  PLoS One       Date:  2016-01-04       Impact factor: 3.240

8.  The Deficiency of Indoleamine 2,3-Dioxygenase Aggravates the CCl4-Induced Liver Fibrosis in Mice.

Authors:  Hideyuki Ogiso; Hiroyasu Ito; Tatsuya Ando; Yuko Arioka; Ayumu Kanbe; Kazuki Ando; Tetsuya Ishikawa; Kuniaki Saito; Akira Hara; Hisataka Moriwaki; Masahito Shimizu; Mitsuru Seishima
Journal:  PLoS One       Date:  2016-09-06       Impact factor: 3.240

9.  Effects of indoleamine 2,3-dioxygenase deficiency on high-fat diet-induced hepatic inflammation.

Authors:  Junji Nagano; Masahito Shimizu; Takeshi Hara; Yohei Shirakami; Takahiro Kochi; Nobuhiko Nakamura; Hirofumi Ohtaki; Hiroyasu Ito; Takuji Tanaka; Hisashi Tsurumi; Kuniaki Saito; Mitsuru Seishima; Hisataka Moriwaki
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

10.  Enhanced development of azoxymethane-induced colonic preneoplastic lesions in hypertensive rats.

Authors:  Takahiro Kochi; Masahito Shimizu; Tomohiko Ohno; Atsushi Baba; Takafumi Sumi; Masaya Kubota; Yohei Shirakami; Hisashi Tsurumi; Takuji Tanaka; Hisataka Moriwaki
Journal:  Int J Mol Sci       Date:  2013-07-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.